Patents Examined by Sean E Aeder
  • Heterodimeric proteins
    Patent number: 10738133
    Abstract: The invention provides novel heterodimeric proteins including heterodimeric antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: August 11, 2020
    Assignee: Xencor, Inc.
    Inventors: Gregory Moore, Matthew Bernett, Rumana Rashid, John Desjarlais
  • Diagnosis of cancer by detecting auto-antibodies against PAR1
    Patent number: 10732184
    Abstract: The present invention relates to a method for diagnosis of a cancer, comprising the steps of (i) determining the level of antibodies against protease-activated receptor 1 (PAR1) in a sample from a subject to be diagnosed, (ii) comparing the determined level in the sample to a control level derived from subjects without ovarian cancer; wherein a decreased level in the sample from the subject to be diagnosed as compared to the control level is indicative for ovarian cancer in the subject. Furthermore the invention relates to differential diagnosis of cancer and the prediction of the response of a subject to be treated for cancer with a drug.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: August 4, 2020
    Assignee: CellTrend GmbH
    Inventors: Harald Heidecke, Kai Schulze-Forster
  • Chemoimmunotherapy for epithelial cancer
    Patent number: 10722523
    Abstract: The invention provides a method for treating cancer in a subject in need thereof, wherein said subject comprises cancer tissue that ‘contains epithelial cancer cells and immunosuppressive 8 cells, and wherein said method comprises administering to said subject a therapeutically effective amount of a) one or more first composition that pauses—immunogenic eel’ death and/or of said epithelial cancer cells, and b) one or more second composition that reduces one or both of the number and function of said immunosuppressive B cells in said cancer.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: July 28, 2020
    Assignee: The Regents of the University of California
    Inventors: Michael Karin, Shabnam Shalapour
  • Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates
    Patent number: 10722549
    Abstract: Methods for the treatment of CD30-expressing cancers are provided. The methods comprise administering to a subject in need thereof a weekly dose of from about 0.8 mg/kg to about 1.8 mg/kg of an antibody-drug conjugate compound having formula (I); or a pharmaceutically acceptable salt thereof; wherein: mAb is an anti-CD30 antibody unit, S is a sulfur atom of the antibody, A- is a Stretcher unit, and p is from about 3 to about 5.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: July 28, 2020
    Assignee: SEATTLE GENETICS, INC.
    Inventors: Eric Sievers, Dana Kennedy
  • Peptides and combination of peptides for use in immunotherapy against NHL and other cancers
    Patent number: 10702593
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: July 7, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Peptides and combination of peptides for use in immunotherapy against NHL and other cancers
    Patent number: 10702592
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 17, 2019
    Date of Patent: July 7, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Oliver Schoor, Andrea Mahr, Toni Weinschenk, Anita Wiebe, Jens Fritsche, Harpreet Singh
  • Anti-GITR antibodies for cancer diagnostics
    Patent number: 10690674
    Abstract: Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: June 23, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Xi-Tao Wang, Olufemi A. Adelakun, Anne C. Lewin, Alan J. Korman, Mark J. Selby, Changyu Wang, Haichun Huang, Karla A. Henning, Nils Lonberg, Mohan Srinivasan, Michelle Minhua Han, Guodong Chen, Richard Y. Huang, Indrani Chakraborty, Susan Chien-Szu Wong, Huiming Li
  • AntiPlexin A1 agonist antibody
    Patent number: 10688178
    Abstract: Provided is a novel anti-Plexin-A1 agonist antibody that promotes dendritic cell contraction. Also provided is a pharmaceutical composition comprising such an antibody and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: June 23, 2020
    Assignees: Osaka University, Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsushi Kumanogoh, Ryusuke Omiya, Hiroyuki Tsunoda, Takeshi Baba, Sachiyo Suzuki, Yuri Teranishi
  • Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
    Patent number: 10675349
    Abstract: The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: June 9, 2020
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Wayne A. Marasco, Quan Zhu, De-Kuan Chang
  • Antibodies having specificity to nectin-4 and uses thereof
    Patent number: 10675357
    Abstract: The present invention relates to antibodies having specificity to nectin-4 and uses thereof.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: June 9, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES
    Inventors: Marc Lopez, Daniel Olive
  • Anti-CD89 cytotoxic complex
    Patent number: 10668147
    Abstract: Complexes suitable for targeting and killing a human target cell comprising a first polypeptide with a binding structure for binding the complex to the cellular surface receptor CD89 (e.g. with an anti CD89 antibody) presented on the cell surface of the human target cell and a second polypeptide comprising a toxic effector domain, preferably Pseudomonas exotoxin A); to nucleic acid molecules encoding said complexes, vectors, host cells containing the nucleic acids and methods for preparation and producing such complexes; compositions and methods for using said complexes for the treatment of diseases, in particular of cancer diseases like leukemia.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: June 2, 2020
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V., RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN
    Inventors: Christoph Stein, Radoslav Mladenov, Bernhard Stockmeyer, Stefan Barth, Lea Christin Schenke, Rainer Fischer
  • Biomarkers to identify patients that will respond to treatment and treating such patients
    Patent number: 10648038
    Abstract: The invention relates to methods for using biomarkers to identify cancer patients that will or are likely to respond to treatment. Specifically, the invention relates to the use of one or more of three association studies of cancer types, gene mutations, or gene expression levels in order to identify cancer patients that will or are likely to respond to treatment with a histone deacetylase (HDAC) inhibitor, alone or in combination with another cancer treatment. The methods may, optionally, further include treating such patient with an HDAC inhibitor, alone or in combination with another cancer treatment.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: May 12, 2020
    Assignee: Acetylon Pharmaceuticals, Inc.
    Inventors: Min Yang, Simon Steward Jones
  • Drug selection for non-small cell lung cancer therapy
    Patent number: 10640830
    Abstract: The present invention provides methods for selecting a suitable anticancer drug for the treatment of patient with non-small cell lung cancer (NSCLC). The present invention also provides methods for determining drug resistance in NSCLC patients receiving EGFR inhibitor therapy.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: May 5, 2020
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Sharat Singh, Phillip Kim, Steven Lockton
  • Chimeric antigen receptor and methods of use thereof
    Patent number: 10632152
    Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: April 28, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
  • Carrier-binding agent compositions and methods of making and using the same
    Patent number: 10618969
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: April 6, 2016
    Date of Patent: April 14, 2020
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Methods of detecting cancer
    Patent number: 10613090
    Abstract: The present disclosure is directed toward methods and kits for detecting cancer, and in particular breast cancer, in a subject by measuring the levels of at least one of the identified markers, as compared to a control. The expression of the markers in Table 2A is increased in samples from subjects with cancer as compared to the expression level in subjects without cancer and the expression of the markers in Table 2B are decreased in samples from subjects with cancer as compared to the expression level in subjects without cancer. The sample may be lacrimal secretions or eye wash fluid, saliva, or other biological fluids. The kits may include an eye wash kit, collection tubes and protease inhibitors, or protein stabilizers.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: April 7, 2020
    Assignee: Ascendant Diagnostics, LLC
    Inventors: Anna Daily, Lindsay Rutherford
  • Detecting neoplasm
    Patent number: 10590489
    Abstract: This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: March 17, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: William R. Taylor, Jonathan J. Harrington, Patrick S. Quint, Hongzhi Zou, Harold R. Bergen, III, David I. Smith, David A. Ahlquist
  • Monoclonal anti-GPC-1 antibodies and uses thereof
    Patent number: 10577418
    Abstract: The present application is directed to an invention based on the discovery that the BLCA-38 antibody is actually an antibody population comprising two distinct monoclonal antibodies. The claims define an isolated antibody population comprising first antibodies and/or antigen binding fragments thereof defined by specific heavy chain and light chain variable regions and wherein the antibody population does not contain second antibodies defined by specific light chain variable regions. The claims also define hybridoma cells, cultures capable of producing such antibody populations, compositions comprising such antibody populations, nucleic acid molecules encoding such antibodies, vectors, host cells thereof, and processes for production of the antibody populations of the invention.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: March 3, 2020
    Assignee: Minomic International LTD.
    Inventors: Douglas Campbell, Irene Justiniano Fuenmayor, Aline Nocon, Julie Soon, Quach Truong, Bradley Walsh, Sandra Wissmueller
  • Replication defective adenovirus vector in vaccination
    Patent number: 10563224
    Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: February 18, 2020
    Assignee: Etubics Corporation
    Inventors: Frank R. Jones, Elizabeth Gabitzsch
  • Antibodies against TIM3 and uses thereof
    Patent number: 10533052
    Abstract: Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: January 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Xiao Min Schebye, Mark J. Selby, Michelle Minhua Han, Christine Bee, Andy X. Deng, Anan Chuntharapai, Brigitte Devaux, Huiming Li, Paul O. Sheppard, Alan J. Korman, Daniel F. Ardourel, Ekaterina Deyanova, Richard Huang, Guodong Chen, Michelle Kuhne, Hong-An Truong